DWTX Stock News & Analysis | Latest Updates

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:DWTX) ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

September 3, 2025Investor

DWTX News

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Files For Mixed Shelf Of Up To $150M

HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target

Dogwood Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 60.3%

Dogwood Therapeutics Shares Resume Trading

Dogwood Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 71.7%

Dogwood Therapeutics Shares Resume Trade

Dogwood Therapeutics Shares Halted On Downside; Shares Up 36%

Dogwood Therapeutics Regains Nasdaq Compliance

Dogwood Therapeutics Regains Nasdaq Compliance

Dogwood Therapeutics Announces The Dosing Of The First Patient In Its Phase 2b Clinical Trial Evaluating Halneuron For The Treatment Of Neuropathic Pain Associated With Prior Chemotherapy Treatment

Dogwood Therapeutics Prices $4.8M Registered Direct Offering O 578,9950 Shares At $8.26/Share

Dogwood Therapeutics Converts Existing $19.5M In Debt To Equity

Watching Dogwood Therapeutics; Traders Circulate Newsletter Mention

Dogwood Therapeutics Shares Resume Trade

Dogwood Therapeutics Shares Halted To The Upside, Stock Now Up 25.1%

Dogwood Therapeutics Top Line Data From BHC IMC-2 Long-COVID Study, Demonstrating Clinically Meaningful Reductions In Long-COVID Associated Fatigue And Sleep Disturbance